Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Similar Items

• The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
  by: Zackrisson, B, et al.
  Published: (2004)
• Defining surrogate endpoints for clinical trials in severe Falciparum malaria.
  by: Jeeyapant, A, et al.
  Published: (2017)
• Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
  by: Zackrisson, B, et al.
  Published: (2003)
• Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
  by: Hugosson, J, et al.
  Published: (2003)
• Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
  by: Hugosson, J, et al.
  Published: (2004)